-
Founded in:
1994-09-10 -
Country:
China -
Address:
No. 18, Guoxiang Road, Wujin Economic Development Zone, Jiangsu -
Tax NO.:
913204122509309646 -
Registered Funds:
66 million yuan -
Website:
-
Email:
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Sildenafil citrate |
|
171599-83-0 | 66 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| ENOXAPARIN, [1-3H] |
|
0 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Irbesartan |
It can offset the compensatory mechanism induced by diuretics, enhance the antihypertensive effect of diuretics, selectively block AT1 subtype receptors to exert antihypertensive effects, and weaken the increase in serum uric acid and decrease in blood potassium induced by hydrochlorothiazide.
More
It can offset the compensatory mechanism induced by diuretics, enhance the antihypertensive effect of diuretics, selectively block AT1 subtype receptors to exert antihypertensive effects, and weaken the increase in serum uric acid and decrease in blood potassium induced by hydrochlorothiazide. |
150mg | 138402-11-6 | 65 |
| Hydrochlorothiazide |
It can cause activation of the sympathetic nervous system and renin-angiotensin system, counteract the antihypertensive effect, and reduce blood potassium levels. Combination with irbesartan can enhance the antihypertensive effect.
More
It can cause activation of the sympathetic nervous system and renin-angiotensin system, counteract the antihypertensive effect, and reduce blood potassium levels. Combination with irbesartan can enhance the antihypertensive effect. |
12.5mg | 58-93-5 | 54 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Gliclazide |
This drug is a hypoglycemic sulfonylurea-oral diabetes treatment drug. Gliclazide lowers blood sugar levels by stimulating pancreatic β cells to secrete insulin. For type 2 diabetes, gliclazide can restore the first-phase insulin secretion peak in response to glucose and increase the second-phase insulin secretion. It can be seen that the insulin secretion response induced or stimulated by glucose after a meal is significantly increased.
More
This drug is a hypoglycemic sulfonylurea-oral diabetes treatment drug. Gliclazide lowers blood sugar levels by stimulating pancreatic β cells to secrete insulin. For type 2 diabetes, gliclazide can restore the first-phase insulin secretion peak in response to glucose and increase the second-phase insulin secretion. It can be seen that the insulin secretion response induced or stimulated by glucose after a meal is significantly increased. |
21187-98-4 | 22 |